MNPR vs RTX · $431.4M cap vs P/E 36, rev $88.60B
Monopar Therapeutics Inc (MNPR) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Monopar Therapeutics Inc (MNPR) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported MNPR revenue for 2024-12-31 was $0. Net income was -$15.6M. MNPR currently screens at market cap $431.4M.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
MNPR currently screens at market cap $431.4M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the MNPR and RTX stock pages for the full models.
Not investment advice.